Oramed Pharmaceuticals Inc.
ORMP•NASDAQ•Healthcare•Biotechnology

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEONadav Kidron
Founded2002
Employees4
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.oramed.com
Phone844 967 2633
Address
1185 Avenue of the Americas, Third Floor New York, New York 10036 United States

Corporate Identifiers

CIK0001176309
CUSIP68403P203
ISINUS68403P2039
EIN98-0376008
SIC2834

Leadership Team & Key Executives

Nadav Kidron Esq.
President, Chief Executive Officer and Executive Chairman
Avraham Gabay
Chief Financial Officer, Treasurer and Secretary
Joshua Hexter
Chief Operating and Business Officer
Dr. Miriam Kidron Ph.D.
Chief Scientific Officer and Director